ZS Launches ZAIDYN™ Clinical Development, Expanding Its Digital Life Sciences Platform
17.6.2022 16:45:00 EEST | Business Wire | Press release
Global management consulting and technology firm ZS has announced the launch of ZAIDYN Clinical Development. The offering is the latest expansion of the platform ZAIDYN by ZS, designed to empower life sciences companies to digitally transform and scale customer engagement, field performance, analytics and—now—clinical development design and planning.
“Today, we’re announcing the launch of ZAIDYN Clinical Development, expanding on more than 35 years of software expertise,” said Sanjay Joshi, managing principal and platform lead for ZS. “With ZAIDYN, life sciences organizations can connect their global teams, products, processes, applications, algorithms and data assets for powerful insights to shape clinical research and accelerate clinical development timelines. Our platform works with existing IT systems to fuel efficiency and connectivity, reduce costs and empower life sciences companies of all sizes to innovate, scale and grow as the global healthcare ecosystem evolves.”
ZAIDYN Clinical Development harnesses the power of a self-learning network, AI-driven insights and algorithms to create a fluid, fast, frictionless trial experience for business users, site investigators and patients. With our products, companies have the power to:
- Drive innovation and decision-making throughout the clinical development process with insightful, dynamic reporting and analytics for clinical teams and a high-level view of clinical trial operations for leaders
- Optimize clinical study planning and protocol design using AI and predictive insights that reflect the experiences and perspectives of participants and patients
- Empower teams to test and model site and enrollment scenarios to find ways to make studies more inclusive and engaging, lift participant burden, limit amendments and accelerate trial efficiency
- Create an expanding universe of industry and historical clinical trial data, real-world data, site criteria and patient survey insights
- Raise the bar for clinical research with products built on Amazon Web Services (AWS) that apply the latest clinical data standards and fuel connectivity throughout upstream and downstream systems
More than 130 companies already use ZS’s products to drive business decisions. Now, these companies can combine the clinical expertise of ZS consulting with the latest features of ZAIDYN Clinical Development to break down business and clinical silos and empower teams to work together more efficiently.
“ZAIDYN Clinical Development will help our clients navigate the large-scale, disruptive changes we see happening across our industry—and those on the horizon as AI and machine learning transform clinical research and development (R&D),” said Aaron Mitchell, ZS’s global R&D excellence practice leader. “Smarter platforms for life sciences can help us improve clinical trial diversity, bring life-saving therapies to patients faster, and unlock patterns and breakthroughs that will transform the future of clinical research. It’s all about using insights from data more effectively to drive more inclusive studies and better patient outcomes.”
“With the support of ZS and the ZAIDYN platform, we’re accelerating the transformation we initiated three years ago,” reflected Cynthia Deparis, program manager at Sanofi. “The platform is helping us take a data-driven approach to identifying the best countries and sites for clinical studies. It’s helped us integrate and expand the universe of clinical operational trial data so we can target sites and countries that help us deliver on our development portfolio and think through various strategic parameters like the competitive landscape, our peers’ activity, historical knowledge about sites and feedback from outreached sites. With these insights and the ability to model different scenarios, we can continue to optimize recruitment and enhance the accuracy of our projections, setting our clinical trial development on a continuous improvement cycle.”
About ZS
ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005012/en/
Contact information
Quintin Maidment; ZS@theblissgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom